Fas Apoptosis Inhibitory Molecule Blocks and Dissolves Pathological Amyloid-β Species

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Neurodegenerative diseases like Alzheimer's disease (AD) are linked to the buildup of misfolded proteins, such as amyloid-beta (Aβ).
• These protein aggregates form insoluble deposits, contributing to disease progression.
• Current research seeks molecules that can break down these aggregates to potentially reverse disease effects.

Purpose of the Study:

• To investigate the role of Fas Apoptosis Inhibitory Molecule (FAIM) in the context of protein aggregation in neurodegenerative diseases.
• To determine if FAIM can prevent or reverse the formation of amyloid-beta (Aβ) aggregates.

Main Methods:

• Studied FAIM-deficient Neuro 2A cells to observe Aβ accumulation.
• Utilized recombinant human FAIM in cell-free systems to assess its effects on Aβ oligomers and fibrils.
• Assessed the ability of recombinant human FAIM to disaggregate and solubilize pre-formed Aβ fibrils.

Main Results:

• FAIM-deficient cells showed accumulation of Aβ oligomers and fibrils.
• Recombinant human FAIM inhibited the formation of pathological Aβ oligomers and fibrils in a cell-free system.
• Recombinant human FAIM demonstrated the ability to disaggregate and solubilize existing Aβ fibrils.

Conclusions:

• FAIM possesses a novel function in preventing and resolving amyloid-beta (Aβ) aggregation.
• FAIM is a potential therapeutic candidate for neurodegenerative diseases characterized by protein misfolding.
• This finding opens new avenues for treating irreversible neurological conditions.